Non-nicotinic neuropharmacological strategies for nicotine dependence: Beyond bupropion

Drug Discovery Today

Volumn 8, Issue 22, 2003, Pages 1025-1034

  Cryan, John F ^a   Gasparini, Fabrizio ^a   Van Heeke, Gino ^b   Markou, Athina ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Addiction; COPD; CRF; D3 receptor; Dependence; Drug Discovery; GABAB; MGLUR5; Molecular Medicine; Nicotine; Pharmaceutical Science; Pharmacology; Physiology; Smoking cessation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMFEBUTAMONE; AMPA RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BACLOFEN; BP 897; CANNABINOID RECEPTOR ANTAGONIST; CGP 44532; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; EGLUMETAD; MECAMYLAMINE; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; REBOXETINE; SB 277011 A; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

BLOOD DISEASE; CHEWING GUM; CHOLINERGIC SYSTEM; CIGARETTE SMOKING; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG FORMULATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REVIEW; SMOKING CESSATION; TRANSDERMAL PATCH; WITHDRAWAL SYNDROME;

ANIMALS; BUPROPION; DISEASE MODELS, ANIMAL; EXTINCTION, PSYCHOLOGICAL; HUMANS; NICOTINE; REINFORCEMENT SCHEDULE; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 0348141705     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02890-3     Document Type: Review

References (89)

1. Munafo M., et al. Smoking Cessation Matters in Primary Care. 2003;Radcliffe Medical Press.
2. Anderson J.E., et al. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest. 121:2002;932-941.
3. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology (Berl.). 117:1995;2-10.
4. Hughes J.R., et al. Recent advances in the pharmacotherapy of smoking. J.A.M.A. 281:1999;72-76.
5. Hayford K.E., et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry. 174:1999;173-178.
6. Murray R.P., et al. Intervention for relapse to smoking: the lung health study restart programs. Addict. Behav. 22:1997;281-286.
7. Balfour D.J. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int. J. Clin. Pract. 55:2001;53-57.
8. Markou A., Kenny P.J. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotox. Res. 4:2002;297-313.
9. Lerman C., et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 67:2002;219-223.
10. Glassman A.H., et al. Smoking, smoking cessation and major depression. J.A.M.A. 264:1990;1546-1549.
11. Jorenby D.E., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340:1999;685-691.
12. Markou A., et al. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 18:1998;135-174.
13. Kotlyar M., et al. Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy. 21:2001;1530-1548.
14. Cryan J.F., et al. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl.). 168:2003;347-358.
15. Ascher J.A., et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry. 56:1995;395-401.
16. Cryan J.F., et al. Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J. Pharmacol. Exp. Ther. 298:2001;651-657.
17. Li S.X., et al. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology. 42:2002;181-190.
18. Meyer J.H., et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl.). 163:2002;102-105.
19. Slemmer J.E., et al. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295:2000;321-327.
20. Glick S.D., et al. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur. J. Pharmacol. 448:2002;185-191.
21. Bruijnzeel A.W., Markou A. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse. 50:2003;20-28.
22. Shoaib M., et al. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl.). 165:2003;405-412.
23. Rauhut A.S., et al. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl.). 169:2003;1-9.
24. Rose J.E., et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:1994;86-99.
25. Young R., Glennon R.A. Nicotine and bupropion share a similar discriminative stimulus effect. Eur. J. Pharmacol. 443:2002;113-118.
26. Kenny P.J., Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. 70:2001;531-549.
27. Dani J.A. Roles of dopamine signaling in nicotine addiction. Mol. Psychiatry. 8:2003;255-256.
28. Kosten T.R., et al. The potential of dopamine agonists in drug addiction. Expert Opin. Investig. Drugs. 11:2002;491-499.
29. Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol. Neurobiol. 11:1995;1-19.
30. Hayes P.E., Kristoff C.A. Adverse reactions to five new antidepressants. Clin. Pharm. 5:1986;471-480.
31. Preti A. Vanoxerine national institute on drug abuse. Curr. Opin. Investig. Drugs. 1:2000;241-251.
32. Le Foll B., et al. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry. 15:2000;140-146.
33. Le Foll B., et al. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse. 47:2003;176-183.
34. Pilla M., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 400:1999;371-375.
35. Di Ciano P., et al. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology. 28:2003;329-338.
36. Vorel S.R., et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 22:2002;9595-9603.
37. Le Foll B., et al. Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol. Psychiatry. 8:2003;225-230.
38. Andreoli M., et al. Selective antagonism at dopamine D(3) receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology. 28:2003;1272-1280.
39. Benwell M.E., Balfour D.J. Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur. J. Pharmacol. 325:1997;13-20.
40. Fu Y., et al. Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: An in vivo microdialysis study. J. Neurosci. 21:2001;8979-8989.
41. Klimek V., et al. Effects of long-term cigarette smoking on the human locus coeruleus. Arch. Gen. Psychiatry. 58:2001;821-827.
42. Rauhut A.S., et al. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J. Pharmacol. Exp. Ther. 303:2002;664-672.
43. Linner L., et al. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther. 297:2001;540-546.
44. da Costa C.L., et al. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest. 122:2002;403-408.
45. Balfour D.J., Ridley D.L. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction? Pharmacol. Biochem. Behav. 66:2000;79-85.
46. Seth P., et al. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol. Biochem. Behav. 71:2002;795-805.
47. Harrison A.A., et al. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology. 25:2001;55-71.
48. Rasmussen K., et al. The novel 5-hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J. Pharmacol. Exp. Ther. 294:2000;688-700.
49. Grottick A.J., et al. Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology (Berl.). 157:2001;292-298.
50. Tzschentke T.M., Schmidt W.J. Glutamatergic mechanisms in addiction. Mol. Psychiatry. 8:2003;373-382.
51. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
52. Blaha C.D., et al. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. Eur. J. Neurosci. 9:1997;902-911.
53. Schilstrom B., et al. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience. 82:1998;781-789.
54. Kelsey J.E., et al. Low doses of dizocilpine block the development and subsequent expression of locomotor sensitization to nicotine in rats. Psychopharmacology (Berl.). 161:2002;370-378.
55. Kenny P.J., et al. Group II metabotropic and alpha-amino-3-hydroxy-5- methyl-4-isoxazole propionate (AMPA)/Kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J. Pharmacol. Exp. Ther. 306:2003;1068-1076.
56. Helton D.R., et al. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology. 36:1997;1511-1516.
57. Chiamulera C., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4:2001;873-874.
58. Paterson N.E., et al. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl.). 167:2003;257-264.
59. Kalivas P.W. Neurocircuitry of addiction. Davis K.L., et al. Neuropsychopharmacology: the Fifth Generation of Progress. 2002;1357-1366 Lipincott Williams and Wilkins, Philadelphia.
60. Bowery N.G., et al. International union of pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol. Rev. 54:2002;247-264.
61. Hughes J.R., et al. Anxiolytics for smoking cessation. Cochrane Database Syst. Rev. 4:2000;CD002849.
62. Paterson N.E., Markou A. Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse. 44:2002;252-253.
63. Dewey S.L., et al. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 31:1999;76-86.
64. Ashby C.R. Jr, et al. Systemic administration of 1R,4S-4-amino-cyclopent- 2-ene-carboxylic acid, a reversible inhibitor of GABA transaminase, blocks expression of conditioned place preference to cocaine and nicotine in rats. Synapse. 44:2002;61-63.
65. Krauss G.L., et al. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 50:1998;614-618.
66. B receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl.) (in press).
67. Fattore L., et al. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol. 37:2002;495-498.
68. Corrigall W.A., et al. Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl.). 149:2000;107-114.
69. Corrigall W.A., et al. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl.). 158:2001;190-197.
70. Fadda P., et al. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse. 50:2003;1-6.
71. Ling W., et al. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology. 18:1998;403-404.
72. Brebner K., et al. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. 37:2002;478-484.
73. Addolorato G., et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 37:2002;504-508.
74. Urwyler S., et al. N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro- pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of γ-aminobutyric acidB receptor function. J. Pharmacol. Exp. Ther. 307:2003;322-330.
75. Pin J.P., et al. Positive allosteric modulators for gamma-aminobutyric acid(B) receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors. Mol. Pharmacol. 60:2001;881-884.
76. Valjent E., et al. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135:2002;564-578.
77. Castane A., et al. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology. 43:2002;857-867.
78. Cossu G., et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118:2001;61-65.
79. Cohen C., et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13:2002;451-463.
80. Tzavara E.T., et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138:2003;544-553.
81. Sarnyai Z., et al. The role of corticotropin-releasing factor in drug addiction. Pharmacol. Rev. 53:2001;209-243.
82. Shaham Y., et al. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res. Brain Res. Rev. 33:2000;13-33.
83. Matta S.G., et al. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology. 23:1998;103-113.
84. Buczek Y., et al. Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology (Berl.). 144:1999;183-188.
85. Shaham Y., et al. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl.). 137:1998;184-190.
86. Lindblom N., et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 69:2002;254-260.
87. Cohen C., et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. 306:2003;407-420.
88. Rose J.E. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. 67:2000;71-81.
89. Lerman C., Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am. J. Med. Genet. 118B:2003;48-54.